IE83503B1 - Crystalline oxathiolane derivatives - Google Patents
Crystalline oxathiolane derivativesInfo
- Publication number
- IE83503B1 IE83503B1 IE1992/1780A IE921780A IE83503B1 IE 83503 B1 IE83503 B1 IE 83503B1 IE 1992/1780 A IE1992/1780 A IE 1992/1780A IE 921780 A IE921780 A IE 921780A IE 83503 B1 IE83503 B1 IE 83503B1
- Authority
- IE
- Ireland
- Prior art keywords
- crystalline form
- pyrimidin
- hydroxymethyl
- amino
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
Abstracts T.C.O.1 and M.C.P. 63; European Patent Application Publication No. 0382562). The compound of formula (I) is a racemic mixture of the two enantiomers of formulae (l—1) and (I-2):- l )\ 0- o ry (I-1) o HOCH2 O 2 ( : E s S and was described and tested in the form of its racemate. The only compound currently approved for the treatment of conditions caused by HIV is 3'—azido-3'- deoxythymidine (AZT, zidovudine, BW 509U). However, this compound has a significant side—effect liability and thus either cannot be employed or, once employed, may have to be withdrawn in a significant number of patients.There is in consequence a continuing need to provide compounds which are effective against HIV but with a concomitant significantly better therapeutic index.
Description
Crystalline Oxathiolane Derivatives Description The present invention relates to nucleoside analogues and their use in medicine. More specifically the invention is concerned with 1,3-oxathiolane nucleoside analogues, particular physical form thereof, pharmaceutical formulations thereof and the use thereof in the treatment of viral infections.
The compound of formula (I) also known as BCH—189 or NGPB—21 has been described as having antiviral activity in particular against the human immunodeficiency viruses (HlV‘s), the causative agents of AIDS (5th Anti—Aids Conference, Montreal, Canada 5th-9th June 1989: Abstracts T.C.O.1 and M.C.P. 63; European Patent Application Publication No. 0382562). The compound of formula (I) is a racemic mixture of the two enantiomers of formulae (l—1) and (I-2):- l )\ 0- o ry (I-1) o HOCH2 O 2 ( : E s S and was described and tested in the form of its racemate. The only compound currently approved for the treatment of conditions caused by HIV is 3'—azido-3'- deoxythymidine (AZT, zidovudine, BW 509U). However, this compound has a significant side—effect liability and thus either cannot be employed or, once employed, may have to be withdrawn in a significant number of patients.There is in consequence a continuing need to provide compounds which are effective against HIV but with a concomitant significantly better therapeutic index.
Although the enantiomers of the compound of formula (I) are equipotent against HIV the(—)-enantiomer has considerably lower cytotoxicity than the other enantiomer and is thus the preferred compound as an antiviral agent.
The (+enantiomer has the chemical name (-)gi_s4—Amino-1—(2— hydroxymethyl-1 ,3-oxathiolan-5—yl)—( 1 H)- pyrimidin-2—one. It has the absolute stereochemistry of the compound of formula (l—1) which has the name (2R,cis)) amino(2-hydroxymethyl-1,3—oxathiolanyl)-(1H)—pyrimidinone. The compound is now known as 3TC.
Preferably 3TC will be substantially free of the corresponding (+)—enantiomer, that is to say no more than about 5% w/w of the (+)- enantiomer, preferably no more than about 2%, in particular less than about 1% w/w is present. international application PCT/GB91/00706, publication no W091/17159 describes the preparation of 3TC, its antiviral activity and its use in medicine. 3TC is described and prepared in WO91/17159 as a freeze dried powder.
We have now found that 3TC can be obtained in crystalline form and exhibits polymorphism.
When crystallised from aqueous solution 3TC is obtained in the form of needle—shaped crystals (hereinafter Form I). In this form the crystals are not favoured for pharmaceutical formulation into solid dosage forms because of their physical properties, for example poor flow characteristics. We have further found that under certain conditions 3TC may be obtained in the form of substantially bipyramidyl crystals (hereinafter Form ii). The crystal habit of Form H has improved flow characteristics and is thus preferred in the manufacture of solid dosage forms.
In addition Form l crystals are a less stable polymorphic forms and certain pharmaceutical unit operations such as milling may cause conversion of Form l to Form ii, an undesirable characteristic for manufacture of solid dosage forms.
TC in the form of bipyramidyl crystals has a melting point of greater than about 170°C, in particular 177-178°C when pure. 3TC in the form of needle-like crystals has a melting point of less than about 130°C in particular about 124—127°C in pure form. ' 3TC in Form ll exhibits characteristic absorption bands in its infra red (i.r.) spectrum which are absent from the i.r. spectrum of Form l. In particular Form ll exhibits strong absorption bands at ~92O and ~85O wavenumbers. Further, a characteristic band of Form l at 1110 wavenumbers is absent from the spectrum of Form ll.
Form ll of 3TC further shows a characteristic endotherm with an onset temperature at 177-178°C in its differential scanning calorimetry (DSC) profile. By contrast Form I shows a characteristic endotherm in its DSC profile with an onset temperature at 124-127°C. in a first aspect of the invention there is provided 3TC in the form of bipyramidal crystals.
In a yet further aspect of the invention there is provided 3TC in bipyramidal crystalline form and having a melting point of greater than 170°C, in particular 177- 178°C. In an alternative aspect there is provided 3TC in bipyramidal crystalline form and having in its DSC profile an endotherm with an onset temperature of 177—178°C.
In a yet further alternative there is provided 3TC in bipyramidal crystalline form and having absorption bands at about 920 and about 850 wavenumbers in its infra red spectrum. in particular there is provided 3TC in which in addition to absorption bands at these wavenumbers a band at 1110 wavenumbers is substantially absent.
TC may be obtained from its racemate by resolution by any method known in the art for the separation of racemates into their constituent enantiomers. in particular 3TC may be obtained from the known racemate by chiral H PLC, by enzyme mediated enantioselective catabolism with a suitable enzyme such as cytidine deaminase or by selective enzymatic degradation of a suitable derivative using a 5'-nucleotide. Suitable methods for preparing 3TC are described in W091/17159.
TC in the form of needle shaped crystals may be obtained by crystallisation of the compound from aqueous solution or by azeotropic distillation with propanol.
TC in the form of the preferred bipyramidyl shaped crystals may be obtained by recrystallisation from non—aqueous media, in particular a lower (C2_5) alcohol, for example ethanol, IMS (industrial methylated spirit) or propanol. In a preferred method 3TC in bipyramidyl form may be obtained from 3TC in needle form by ageing the latter in industrial Methylated Spirit (IMS) or ethanol at elevated T3 temperature (e.g. 30—70°, particularly about 50°C) for an appropriate time (e.g. 0.5- 3hrs, in particular about 1 hour or more).
Alternatively 3TC in bipyramidyl form may be obtained by heating the compound in needle form above its melting point of 124-127°, in particular above about 170°C, for example above about 177-178°C and allowing the melt to cool. ln a further alternative 3TC in bipyramidyl form may be obtained by grinding or milling the compound in the form of needle shaped crystals.
Preferably 3TC is in the form of bipyramidyl shaped crystals substantially free of needle crystals. Where these crystals are obtained by recrystallisation or ageing in liquid media the compound will normally be obtained entirely free of needle shaped crystals.
TC in crystalline form may be used as an antiviral agent as described in W091/17159 which is incorporated herein by reference.
TC in crystalline form may be formulated as a pharmaceutical formulation for use as an antiviral agent in described in W091/17159.
Figure 1 shows 3TC in the form of needle shaped crystals (Form I).
Figure 2 shows 3TC in the form of bipyramidyl shaped crystals (Form ll).
Figure 3 is an infra—red spectrum of Form l crystals.
Figure 4 is an infra--red spectrum of Form ll crystals.
Figure 5 is a DSC thermogram of Form l crystals.
Figure 6 is a DSC thermogram of Form ll crystals.
The following examples illustrate the invention but are not intended as a limitation thereof. All temperatures are in °C.
INTERMEDIATE 1 -Methoxv~1,3—oxathiolane—2—methanol, benzoate.
A solution of zinc chloride (1 .6g) in hot methanol (15ml) was added to a stirred solution of mercaptoacetaldehyde, dimethyl acetal (34.2g) and benzoyloxy acetaldehyde (48.39) in toluene (1300ml) which was then heated to reflux under nitrogen for 50 min. The cooled mixture was concentrated, diluted with some toluene, then filtered through Kiesulguhr.The combined filtrates and toluene were washed with aqueous saturated sodium bicarbonate solution (x2) and brine, dried (MgSO4) then evaporated to an oil which was subjected to column chromatography on silica (2kg, Merck 9385 ) eluted with chloroform to give the title product as an oil (45.1g) a mixture of anomers (ca 1:1); 1H NMR (DMSO-d5) 3.1—3.3(4H), 3.42(6H), 4.4-4.6 (4H), 5.41(1H), 5.46 (1H), 5.54 (1H), 5.63 (1H), 7.46 (4H), 7.58 (2H), 8.07 (4H); ymax (CHBr3)1717.6cm‘1.
INTERMEDIATE 2 (flcis-1—(2—Benzoyloxymethyl-1 ,3-oxathiolan-5—yl)-( 1 H)-pyrimidin-2~4—dione A mixture of finely ground uracil (9.62g) hexamethyl disilazane (50 ml) and ammonium sulphate (30 mg) was heated at reflux under nitrogen until a clear solution was obtained. This was cooled and then evaporated to a colourless oil, which was dissolved, under nitrogen atmosphere, in acetonitrile (100m|). The solution was added to a stirred ice cooled solution of 5-methoxy—1,3-oxathiolane methanol, benzoate (intermediate 1) (19.43g), in acetonitrile (600ml) and trimethyl silyl trifluoromethanesulphonate (14.7ml) was added. The ice bath was removed, and the solution was heated at reflux under nitrogen for 45 mins. After cooling and evaporation, the residue was purified by column chromatography over 1kg of silica gel (Merck 9385) eluting with chloroform/methanol 9:1. Appropriate fractions were cooled and evaporated to afford a crude residue.This was fractionally crystallized from the minimum of hot methanol (c.1200ml) to afford the title compound (6.329) as white crystals. 1H NMR(d5DMSO) 6 11.36 (1H,bs). 7.50-8.00 (6H,m), 6.20 (1H,t), .46 (2H,m), 4,62 (2H, m), 3.48 (1H, m), 3.25 (1H, m).
INTERMEDIATE 3 (1)-(cis)-4—Amino—1-(2-benzovloxymethyl-1 ,3—oxathiolanyl)-( 1 H)-pyrimidinone Method (a) A suspension of cytosine (20.705g) and ammonium sulphate (few mgs) in hexamethyldisilazane (110m|) was stirred and heated at reflux for 2‘/zh, under nitrogen. Solvent was removed by evaporation, and the residual solid was dissolved in dry acetonitrile (350ml). This solution was transferred using flexible needle techniques into a stirred, ice—chi|led solution of 5-methoxy-1 ,3-oxathiolane methanol, benzoate (Intermediate l) (43.57g) in acetonitrile (650ml) under nitrogen.
Trimethylsilyl trifluoromethanesulphonate (33ml) was added, the solution was allowed to warm to ambient temperature (11/2h) then heated to reflux for an overnight period. The residue mixture was concentrated, diluted with saturated aqueous sodium bicarbonate solution (500ml), then extracted with ethyl acetate (3x500ml).The combined extracts were washed with water (2x250ml) and brine (250m|) dried (MQSO4) then evaporated to a foam which was subjected to column chromatography on silica (600g, merck 7734), eluted with ethyl acetate-methanol mixtures to give a mixture of anomers (ca 1:1 31.59g). The mixture was crystallised from water (45ml) and ethanol (9.0m|) to give a solid (10.23g) which was recrystallised from ethanol (120ml) and water (30ml) to give the title product as a white solid (9.26g); /lmax (MeOH) 229.4mm (E1% 610); 272.4mm (E1% 1cm 1cm 293); 1H NMR (DMSO d6) 6 3.14 (1H), 3.50 (1H), 4.07 (2H), 5.52 (1H), 5.66 (1H), 6.28 (1H), 7.22 (2H), 7.56 (2H), 7.72 _(2H), 8.10 (2H).
Method (bl Phosphorus oxychloride (7.0ml) was added dropwise to a stirred, ice—cooled suspension of 1,2,4—triazole (11.65g) in acetonitrile (120ml) then, keeping the internal temperature below 15°C, triethylamine (22.7ml) was added dropwise. After min a solution of (_t)«cis —1—(2—benzoyloxymethyl-1,3~oxathiolanyl)~(1 H)- pyrimidin—2,4—dione (intermediate 2) (6.279) in acetonitrile (330m|) was slowly added.
Stirring was then continued at room temperature overnight. The mixture was cooled by means of an ice bath and triethylamine (30ml) was slowly added followed by water (21ml). The resultant solution was evaporated, and the residue was partitioned between saturated sodium bicarbonate solution (400ml) and chloroform (3x200ml).
The combined chloroform extracts were dried and magnesium sulphate, filtered and evaporated to give a crude residue (9.7g).The residue was dissolved in 1,4-dioxan (240ml) and concentrated aqueous ammonia solution (s.g 0.880, 50ml) was added.
After 1%h the solution was evaporated and the residue dissolved in methanol. This caused precipitation of a solid, which was filtered off. The mother liquors were purified by column chromatography over silica gel (Merck 9385, 600g). Appropriate fractions were pooled and evaporated to give the title compound as a fawn solid (2.18g), identical to that obtained by Method (a).
INTERMEDIATE 4 (i)—(cis)—4-Amino-1j2—hyd roxymethyl~1 ,3—oxathiolanyl)~( 1 H)—pyrimidinone A suspension of (cis)—4-amino(2-benzoyloxymethyl-1,3-oxathiolanyl)- (1H)-pyrimidin—2-one (Intermediate 3) (8199) and Amberlite IRA—400 (OH) resin (8.24g) in methanol (250ml) was stirred and heated to reflux for 1‘/4h. Solids were removed by filtration then washed with methanol. The combined filtrates were evaporated. The residue was triturated with ethyl acetate (80ml). The resulting white solid was collected by filtration to give the title product (5.09g), 1H NMR (DMSO-(I5) 3.04 (1H), 3.40 (1 H), 3.73 (2H), 5.18 (1H), 5.29 (1H), 5.73 (1 H), 6.21 (1H), 7.19 (2H), 7,81 (1H).
INTERMEDIATE 5 (~)-cis—4—Amino(2—hvdroxvmethvl—1 ,3-oxathiolanvl)-(1 H) pvrimidinone (i) Three 50ml flasks of nutrient broth (Oxoid Ltd) were inoculated with a loopful each of Escherichia coli (ATCC 23848) scraped from a Nutrient Agar plate.The flasks were incubated overnight at 37°C with shaking at 250 rev/min and then each flask was used to inoculate 41 of CDD medium (glutamic acid, 3g/1; MgSO4, 0.2g/1: K2804, 2.5g/1; NaCl, 2.3g/1, Na2HPO42H20, 1.1g/1, NaH2PO42H20 0.6g/I cytidine, 1.2g/I) in a seven litre fermenter. The cultures were fermented at 750 rev/min, 37°C with aeration at 41/min. After growth for 24hrs the cells were collected by centrifugation (5000g, 30 minutes) to yield 72g wet weight.
The cell pellet was resuspended in 300ml of 20mM Tris HCI buffer (pH 7.5) and disrupted by sonication (4 x 45 seconds). The cell debris was removed by centrifugation (30,000 g, 30 minutes) and the protein in the supernatant was precipitated by addition of ammonium sulphate to 75% saturation.The precipitate was collected by centrifugation (30,000g. 30 minutes) and the pellet was resuspended in 25ml of HEPES buffer (100mM, pH 7.0) containing ammonium sulphate (75% saturation). Enzyme solution was prepared by centrifugation at 12,000 rpm for 30 mine. The supernatant was discarded and the pellet dissolved in Tris HCI buffer (pH 7.0; 100mM) to the original volume. (ii) Intermediate 4 (115mg was dissolved in water (100m|), and stirred.
Enzyme solution (0.5mI) was added, and the mixture was maintained at a constant pH by the continual addition of HCI (25mM). The conversion was monitored by chiral HPLC, which showed that the (+) enantiomer of the substrate was preferentially deaminated. After 22hr the (+) enantiomer of the substrate (RT 12.5min) had been completely removed, and the solution was adjusted to pH 10.5 by the addition of conc. sodium hydroxide.
The solution produced above was eluted through a column of QAE Sephadex (A25; Pharmacia; 30X 1.6cm), pre—equilibrated to pH11. Thecolumn was washed with water (200ml) and then with HCI (0.1M). Fractions (40m|) were taken, and analysed by reversed phase HPLC. Fractions 5-13, containing the unreacted (-) enantiomer of the substrate, were combined and adjusted to pH 7.5 with HCI.
Fraction 47, containing deaminated product, was adjusted to pH7.5 with dil. NaOH.
Analysis by chiral HPLC showed that this material was a mixture, consisting of one enantiomer (RT 10.2min) as the major component with the other enantiomer (RT 8.5min) as a minor component (e.e ca 90%). (iii) Stage (ii) above was repeated on a larger scale. The compound of Example 1 (363mg) in 250ml of water was incubated with enzyme solution (O.5ml), prepared as in Stage (i). Further aliquots (O.5ml) of enzyme were added after 18 and 47 hrs. The reaction mixture was stirred for 70hr., then left standing for a further 64hr. Analysis by chiral hplc indicated that the (+) enantiomer of the substrate had been completely deaminated, and the resulting solution was adjusted to pH 105 with NaOH.
The solution above was loaded onto the same QAE column, and eluted as in stage (i). Fractions 2-6, containing a mixture of the residual substrate and deaminated product, were bulked. Fractions 7-13, containing the residual substrate ((-) enantiomer), were bulked and adjusted to pH 7.5. Fractions 25-26, containing deaminated product, were bulked and neutralised Fractions 2-6 above were re-eluted through the same QAE column. Fractions 3-11 from this second column contained unrected substrate ((-) enantiomer).
Fraction 70 contained the deaminated product. (iv) The resolved substrate fractions from stage (ii) and (iii) were combined and adjusted to pH 7.5. This solution was eluted through a column of XAD-16 (40x2.4cm), packed in water. The column was washed with water, and then eluted with acetone: water (1:4 v/v). Fractions containing the desired (-) enantiomer were bulked and freeze—dried to give a white powder (190mg).
The HPLC methods used above were as follows:— . Reversed Phase analytical HPLC Capital Cartridge Spherisorb ODS—2 Column Eluant Ammonium dihydrogen phosphate (50mM)+ 5% MeCN Flow 1.5ml/min Detection UV, 270nm BCH 189 5.5min deaminated BCH -18~g_8.1min Retention Times . Chiral analytical HPLC Elumn Cyclobond 1 Acetyl 250x4.6mm Eluant 0.2% Triethylammonium acetate (pH7.2) Flow 1.0ml/min Detection UV, 270nm BCH 18911.0 and 12.5min deaminated BCH—189 8.5 and 10.2 min (The bioconversion was followed by monitoring the loss of the peak at 12.5min.. and accumulated of product at Retention Times _ ,J_0~.?—_'3ll02«_. , . J Example 1 (reference example) A suspension of lntermediate 5 (64.8g) in water (200mL) was heated to 45° to give a solution. The solution was cooled to 30°.
The product crystallised as an unstirrable mass. This was broken up and the suspension stirred at 93;; 10° for 1h.
The product was isolated by filtration and washed with ethanol (IMS; 2 x 30mL) then dried in vacuo at 45° for 24h to give 3TC as Form I (fine needle crystals).
The compound had an i.r. spectrum and DSC thennograph identical to Figures 3 and 5 respectively.
Example 2 A suspension of the compound of Example 1 (10.0g) in industrial methylated spirits (IMS; 200mL; 20 volumes) was heated to reflux to give a clear solution. The solution was filtered hot and the filtrate was distilled at atmospheric pressure until 100mL (10 volumes) of solution remained. The solution was seeded with authentic Assay Found: C,41.9; H,4.85; N,18.35 C3H11N3O3S requires: C,41.9; H,4.8; N,18.3% _ The compound had an i.r. spectrum and DSC thermograph identical to Figures 4 and 6 respectively.
Example 3 A suspension of the product of Example 1 (20.0g) in Industrial Methylated Spirits (IMS; 100mL; 5 volumes) was stirred slowly at 50° for 1h.
A small sample (ca 100mg) was removed, dried in vacuo at 50° and examined by microscopy and differential scanning calorimetry (DSC).
The sample was 100% Form ll (bipyramidal habit).
The suspension was stirred at 50° for a further 2h and a sample removed.
Microscopy showed no change.
The suspension was stirred at 50° for 22h, then cooled to 20° and stirred for 1h.
C,41.85; H,4.85; N,18.3 C,41.9; H,4.8; N,18.3°/o Assay Found C3H11N3O3S Requires The product had an i.r. spectrum and DSC thermogram identical to those of Figures 4 and 6 respectively.
Example 4 X-Ray Crystallography data for Form ll Crystal Data : C8H11N3O3S, M = 229.26.
Tetragonal, a = b = 8.749(3), c = 26.523(9)A, V= 203O(2)A3 (by least-squares refinement on diffractometer angles for 14 automatically centred reflections, 1 = 1.54184A).
Space group P43212(No. 96), z= 8, DC: 1.50g cm‘3.
F(0O0) = 960, m(Cu—Ka) = 27.5 cm-1.
Dimensions of data crystal 0.48 x 0.32 x 0.30 mm.
Single crystals of Form ll (colourless bipyramids) were examined by X-ray diffraction. A total of 1651 reflections were measured (3 < 2J < 115°) on a Siemens R3mN diffractometer with monochromatised Cu-Ka radiation and using 2J/w scans.
The structure was solved by direct methods and the non-hydrogen atoms refined anisotropically. The hydrogen atoms attached to carbon were idealised (C-H = 0.96A) and allowed to ride on their parent carbon atoms. Three Hs on -NH2 and —OH groups were located from a difference Fourier map. All H atoms were refined isotropically. Refinement converged to give R = 0.068, Rw = 0.069, W4 = [s2(F) + 0.005[F]2]. Maximum residual electron density was 0.45 eA‘3.The absolute chirality was confirmed using Rogers‘ eta test [h = 099(9)].
Examgle 5 Pharmaceutical Formulations ta) 100mg Tablets Ingredients per tablet The 3TC (Form ll), microcrystalline cellulose and sodium starch glycolate were sieved and blended in a V—blender for about 15 minutes. Sieved magnesium stearate was then added and blending continued for a further 2 minutes.
The blend was compressed in standard tabletting equipment and then film coated with an aqueous suspension of grey Opadry to produce aesthetically acceptable tablets. lb) 300mg Tablets Ingredients per tablet TC (Form ll) 300.0mg Microcrystalline Cellulose NF 279.0mg Sodium Starch Glycolate NF 18.0mg Magnesium Stearate NF £3 Total Weight 600.0mg Tablets were prepared as described in (a) above.
Claims (2)
1.,3—oxathiolan—5—yl)—(1H)~pyrimidinone in the form of bipyramidal crystals which comprises aging the compound in the form of needle shaped crystals in ethanol or industrial methylated spirits at elevated temperature. A method as claimed in claim 12 wherein the needle shaped crystals are prepared by a method which comprises crystallisation of the compound from aqueous solution. A method as claimed in claim 12 wherein the needle shaped crystals are prepared by a method which comprises azeotropic distillation of an aqueous solution of the compound with propan«1—ol. A pharmaceutical formulation comprising (—)~gi_s—4—amino—1—(2- hydroxymethyl~1,3—oxathiolan—5-y|)—(1H)-pyrimidin—2—one in bipyramidal crystalline form and a pharmaceutically acceptable carried thereof. A pharmaceutical formulation as claimed in claim 15 in a form suitable for oral administration. A pharmaceutical formulation as claimed in claim 15 or claim 16 in the form of a tablet or capsule. A method according to any one of Claims 9 - 11 substantially described herein with reference to the examples and/or the accompanying drawings. (—)-$4-Amino-1—(2-hydroxymethyl—1 ,3—oxathiolan—5—yl)-(1H)-pyrimidin- 2—one in bipyramidal crystalline form whenever prepared by a method according to any of Claims 9-11 or 18, substantially as described herein with reference to the examples and/orthe accompanying drawings. A method according to any one of Claims 12-1 4 substantially as described herein with reference to the examples and/or the accompanying drawings. (-)-gigAmino(2-hydroxymethyl-1,3-oxathiolanyl)-(1 H)-pyrimidin-
2.-one whenever prepared by a method according to any of Claims 12- 14 or 20 substantially as described herein with reference to the examples and/or the accompanying drawings. A pharmaceutical formulation according to any one of claims 15-17 substantially as described herein with reference to the examples and/or the accompanying drawings. Tomkins & Co.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBUNITEDKINGDOM03/06/19919111902.4 | |||
| GB919111902A GB9111902D0 (en) | 1991-06-03 | 1991-06-03 | Chemical compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE83503B1 true IE83503B1 (en) | |
| IE921780A1 IE921780A1 (en) | 1992-12-16 |
Family
ID=10696001
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE178092A IE921780A1 (en) | 1991-06-03 | 1992-07-01 | Crystalline oxathiolane derivatives |
| IE20020782A IE20020782A1 (en) | 1991-06-03 | 1992-07-01 | Crystalline oxathiolane derivatives |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE20020782A IE20020782A1 (en) | 1991-06-03 | 1992-07-01 | Crystalline oxathiolane derivatives |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US5905082A (en) |
| EP (2) | EP1099700A1 (en) |
| JP (1) | JP2851480B2 (en) |
| KR (1) | KR100244008B1 (en) |
| AP (1) | AP300A (en) |
| AT (1) | ATE212630T1 (en) |
| AU (2) | AU656379B2 (en) |
| BG (1) | BG60914B1 (en) |
| CA (2) | CA2070230C (en) |
| CZ (1) | CZ284513B6 (en) |
| DE (1) | DE69232387T2 (en) |
| DK (1) | DK0517145T3 (en) |
| ES (1) | ES2171158T3 (en) |
| GB (1) | GB9111902D0 (en) |
| GE (1) | GEP19991834B (en) |
| HK (1) | HK1009599A1 (en) |
| IE (2) | IE921780A1 (en) |
| IL (1) | IL102073A (en) |
| IS (2) | IS1867B (en) |
| MX (1) | MX9202619A (en) |
| NO (1) | NO301713B1 (en) |
| NZ (1) | NZ242981A (en) |
| OA (1) | OA09913A (en) |
| PT (1) | PT517145E (en) |
| RU (1) | RU2102393C1 (en) |
| SG (1) | SG52455A1 (en) |
| SK (1) | SK281249B6 (en) |
| TW (1) | TW254939B (en) |
| UA (1) | UA41265C2 (en) |
| WO (1) | WO1992021676A1 (en) |
| ZA (1) | ZA924007B (en) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4581979A (en) * | 1983-07-01 | 1986-04-15 | Automotive Products Plc | Shipping and installation restraining clip for master cylinder input member |
| US5276151A (en) * | 1990-02-01 | 1994-01-04 | Emory University | Method of synthesis of 1,3-dioxolane nucleosides |
| US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| US5914331A (en) * | 1990-02-01 | 1999-06-22 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
| US6069252A (en) * | 1990-02-01 | 2000-05-30 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers |
| US5444063A (en) * | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
| US6812233B1 (en) | 1991-03-06 | 2004-11-02 | Emory University | Therapeutic nucleosides |
| US5817667A (en) * | 1991-04-17 | 1998-10-06 | University Of Georgia Research Foudation | Compounds and methods for the treatment of cancer |
| GB9116601D0 (en) * | 1991-08-01 | 1991-09-18 | Iaf Biochem Int | 1,3-oxathiolane nucleoside analogues |
| US6177435B1 (en) | 1992-05-13 | 2001-01-23 | Glaxo Wellcome Inc. | Therapeutic combinations |
| US20020120130A1 (en) | 1993-09-10 | 2002-08-29 | Gilles Gosselin | 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents |
| US5587362A (en) * | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
| IL115156A (en) | 1994-09-06 | 2000-07-16 | Univ Georgia | Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines |
| US5703058A (en) * | 1995-01-27 | 1997-12-30 | Emory University | Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent |
| US6391859B1 (en) | 1995-01-27 | 2002-05-21 | Emory University | [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides |
| US5808040A (en) * | 1995-01-30 | 1998-09-15 | Yale University | L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides |
| AU722214B2 (en) | 1995-06-07 | 2000-07-27 | Centre National De La Recherche Scientifique (Cnrs) | Nucleosides with anti-hepatitis B virus activity |
| US5914332A (en) * | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| NZ333099A (en) | 1996-06-25 | 2000-06-23 | Glaxo Group Ltd | synergistic combinations comprising 141W94, zidovudine and 3TC for use in the treatment of HIV |
| US5753789A (en) * | 1996-07-26 | 1998-05-19 | Yale University | Oligonucleotides containing L-nucleosides |
| TW536403B (en) * | 1997-03-24 | 2003-06-11 | Glaxo Group Ltd | An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy |
| US6436948B1 (en) | 2000-03-03 | 2002-08-20 | University Of Georgia Research Foundation Inc. | Method for the treatment of psoriasis and genital warts |
| CA2690137C (en) * | 2001-03-01 | 2012-11-13 | Gilead Sciences, Inc. | Polymorphic and other crystalline forms of cis-ftc |
| US6600044B2 (en) | 2001-06-18 | 2003-07-29 | Brantford Chemicals Inc. | Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers |
| WO2003027106A1 (en) * | 2001-09-25 | 2003-04-03 | Cadila Healthcar Limited | Process for the preparation of crystalline polymorph ii of lamivudine |
| IL163666A0 (en) | 2002-02-22 | 2005-12-18 | New River Pharmaceuticals Inc | Active agent delivery systems and methods for protecting and administering active agents |
| CA2505130C (en) * | 2002-11-08 | 2009-10-06 | Glaxo Group Limited | Pharmaceutical compositions |
| ATE398455T1 (en) | 2003-01-14 | 2008-07-15 | Gilead Sciences Inc | COMPOSITIONS AND METHODS FOR ANTIVIRAL COMBINATION THERAPY |
| ATE415421T1 (en) * | 2004-11-10 | 2008-12-15 | Novartis Vaccines & Diagnostic | DEAMIDATED INTERFERON BETA |
| US20060242012A1 (en) * | 2005-04-22 | 2006-10-26 | Sumit Agarwal | Determining or scoring properties to solicit to join ad network using advertiser or aggregated advertiser interest |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| TWI471145B (en) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | Unitary pharmaceutical dosage form |
| JP5184511B2 (en) * | 2006-04-18 | 2013-04-17 | ルピン・リミテッド | A new crystalline form of lamivudine |
| AR068374A1 (en) * | 2007-09-06 | 2009-11-11 | Combino Pharm Sl | NEW PHARMACEUTICAL COMPOSITIONS OF THE LAMIVUDINA BETA COMPLEX - CICLODEXTRINA |
| US20100190982A1 (en) * | 2007-09-17 | 2010-07-29 | Janardhana Rao Vascuri | Process for the preparation of lamivudine form i |
| WO2009069011A1 (en) * | 2007-11-29 | 2009-06-04 | Ranbaxy Laboratories Limited | Process for the preparation of substituted 1,3-oxathiolanes |
| AU2008331167A1 (en) * | 2007-11-29 | 2009-06-04 | Ranbaxy Laboratories Limited | Process and intermediates for the preparation of substituted 1, 3-oxathiolanes, especially lamivudine |
| WO2009069013A1 (en) * | 2007-11-29 | 2009-06-04 | Ranbaxy Laboratories Limited | Crystalline form i of lamivudine and its preparation |
| WO2009127996A1 (en) * | 2008-04-17 | 2009-10-22 | Ranbaxy Laboratories Limited | Novel crystalline form of lamivudine |
| EP2318398A4 (en) * | 2008-09-01 | 2011-12-07 | Hetero Research Foundation | Process for preparing lamivudine polymorph form |
| EP2350065A1 (en) * | 2008-11-12 | 2011-08-03 | Lupin Ltd. | A novel polymorph of emtricitabine and a process for preparing of the same |
| CN101531656B (en) * | 2009-03-24 | 2010-12-08 | 福建广生堂药业有限公司 | Lamivudine crystal form and preparation method thereof |
| CN101993439B (en) * | 2009-03-24 | 2013-04-24 | 福建广生堂药业股份有限公司 | Lamivudine crystal form and preparation method thereof |
| EP2435052B1 (en) * | 2009-05-27 | 2015-07-15 | Hetero Research Foundation | Solid oral dosage forms of lamivudine with isomalt |
| US8710218B2 (en) | 2009-07-15 | 2014-04-29 | Lupin Limited | Process for preparation of Efavirenz |
| WO2011045815A2 (en) | 2009-10-14 | 2011-04-21 | Matrix Laboratories Ltd. | Process for the preparation of lamivudine and novel salts in the manufacture thereof |
| KR20170078868A (en) | 2010-01-27 | 2017-07-07 | 비이브 헬쓰케어 컴퍼니 | Antibiral therapy |
| US20120295930A1 (en) * | 2010-02-03 | 2012-11-22 | Shankar Rama | Novel process for the preparation of cis-nucleoside derivative |
| CA2789078A1 (en) * | 2010-02-12 | 2011-08-18 | Merck Sharp & Dohme Corp. | Preparation of lamivudine form i |
| US20130115237A1 (en) | 2010-06-09 | 2013-05-09 | Vaccine Technologies, Incorporated | Therapeutic immunization in hiv infected subjects to augment antiretroviral treatment |
| WO2013021290A1 (en) | 2011-08-05 | 2013-02-14 | Lupin Limited | A stereoselective process for preparation of 1,3-oxathiolane nucleosides |
| WO2013168066A1 (en) | 2012-05-05 | 2013-11-14 | Lupin Limited | An improved process for the manufacture of lamivudine form i. |
| CN114099454B (en) * | 2020-08-31 | 2023-06-27 | 长春海悦药业股份有限公司 | Lamivudine tablet and preparation method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047407A (en) * | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
| US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| GB9009861D0 (en) * | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
| US5248776A (en) * | 1990-12-05 | 1993-09-28 | University Of Georgia Research Foundation, Inc. | Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides |
| US5179104A (en) * | 1990-12-05 | 1993-01-12 | University Of Georgia Research Foundation, Inc. | Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides |
-
1991
- 1991-06-03 GB GB919111902A patent/GB9111902D0/en active Pending
-
1992
- 1992-02-06 UA UA93004068A patent/UA41265C2/en unknown
- 1992-06-02 IS IS3873A patent/IS1867B/en unknown
- 1992-06-02 CA CA002070230A patent/CA2070230C/en not_active Expired - Lifetime
- 1992-06-02 CA CA002311988A patent/CA2311988C/en not_active Expired - Lifetime
- 1992-06-02 JP JP4166809A patent/JP2851480B2/en not_active Expired - Lifetime
- 1992-06-02 EP EP01200491A patent/EP1099700A1/en not_active Withdrawn
- 1992-06-02 KR KR1019920009537A patent/KR100244008B1/en not_active IP Right Cessation
- 1992-06-02 AT AT92109221T patent/ATE212630T1/en active
- 1992-06-02 GE GEAP19922654A patent/GEP19991834B/en unknown
- 1992-06-02 NO NO922182A patent/NO301713B1/en not_active IP Right Cessation
- 1992-06-02 PT PT92109221T patent/PT517145E/en unknown
- 1992-06-02 DK DK92109221T patent/DK0517145T3/en active
- 1992-06-02 TW TW081104300A patent/TW254939B/zh not_active IP Right Cessation
- 1992-06-02 DE DE69232387T patent/DE69232387T2/en not_active Expired - Lifetime
- 1992-06-02 AP APAP/P/1992/000395A patent/AP300A/en active
- 1992-06-02 IL IL10207392A patent/IL102073A/en not_active IP Right Cessation
- 1992-06-02 ES ES92109221T patent/ES2171158T3/en not_active Expired - Lifetime
- 1992-06-02 AU AU17361/92A patent/AU656379B2/en not_active Expired
- 1992-06-02 SG SG1996004763A patent/SG52455A1/en unknown
- 1992-06-02 WO PCT/EP1992/001213 patent/WO1992021676A1/en active IP Right Grant
- 1992-06-02 EP EP92109221A patent/EP0517145B1/en not_active Expired - Lifetime
- 1992-06-02 ZA ZA924007A patent/ZA924007B/en unknown
- 1992-06-02 CZ CS932612A patent/CZ284513B6/en not_active IP Right Cessation
- 1992-06-02 AU AU18810/92A patent/AU1881092A/en not_active Abandoned
- 1992-06-02 SK SK1257-93A patent/SK281249B6/en not_active IP Right Cessation
- 1992-06-02 NZ NZ242981A patent/NZ242981A/en not_active IP Right Cessation
- 1992-06-02 US US07/892,029 patent/US5905082A/en not_active Expired - Lifetime
- 1992-06-02 MX MX9202619A patent/MX9202619A/en active IP Right Grant
- 1992-06-02 RU RU93058495A patent/RU2102393C1/en active
- 1992-07-01 IE IE178092A patent/IE921780A1/en not_active IP Right Cessation
- 1992-07-01 IE IE20020782A patent/IE20020782A1/en not_active IP Right Cessation
- 1992-12-04 IS IS4268A patent/IS4268A/en unknown
-
1993
- 1993-11-15 OA OA60437A patent/OA09913A/en unknown
- 1993-11-30 BG BG98254A patent/BG60914B1/en unknown
-
1998
- 1998-08-31 HK HK98110312A patent/HK1009599A1/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IE83503B1 (en) | Crystalline oxathiolane derivatives | |
| AU656379B2 (en) | Crystalline oxathiolane derivatives | |
| US4965374A (en) | Process for and intermediates of 2',2'-difluoronucleosides | |
| US5945547A (en) | Imtermediate in process to make 2', 2'-difluoronucleosides | |
| NO300066B1 (en) | N-oxycarbonyl-substituted 5'-deoxy-5-fluorocytidines | |
| NO180377B (en) | Analogous Process for Preparing Active 1,3-Oxathiolannucleoside Analogs | |
| KR20080039502A (en) | Process for preparing gemcitabine and associated intermediates | |
| US4396623A (en) | Carbocyclic analogs of uracil nucleosides as antiviral agents | |
| US5629454A (en) | Conformationally locked nucleoside analogues | |
| IE882608L (en) | 2',2'-difluoronucleosides | |
| JPH06228186A (en) | 2'-deoxy-@(3754/24)2's)-alkylpyrimidine nucleoside derivative | |
| US20090221811A1 (en) | Process for preparing gemcitabine and associated intermediates | |
| WO2009069011A1 (en) | Process for the preparation of substituted 1,3-oxathiolanes | |
| EP0175180A1 (en) | Histargin-related compounds, a process for their preparation and their use as medicaments | |
| HU187736B (en) | Process for producing /e/ -5-/2-bromovinyl/-2-comma above-deoxyuridine and o-acyl derivatives | |
| US6005097A (en) | Processes for high-yield diastereoselective synthesis of dideoxynucleosides | |
| HU201953B (en) | Process for producing new nucleoside derivatives and pharmaceutical compositions comprising same as active ingredient | |
| EP0850246A2 (en) | Pyrimidine nucleoside derivatives | |
| JPH07188277A (en) | 2'-deoxy-5-fluorouridine derivative | |
| CA1330989C (en) | 2'-2'-difluoronucleosides | |
| FI111723B (en) | (-)-Cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolanyl)-1H-pyrimidinone | |
| Vince | THE SYNTHESES OF NUCLEOSIDE ANALOGS AND THEIR EVALUATION AS INHIBITORS OFADENOSINE DEAMINASE |